1
|
Song J, Peng D, Peng Y, Zhao G, Ren Y, Guo L, Ren L, Zhang X, Xie X, Zhang Y, Cao L, Li Y. The new pattern for dual NOTCH pathway involving nuclear transcription and mitochondrial regulation supports therapeutic mechanism of 4-butyl benzophenone derivatives against SIRS. Free Radic Biol Med 2024; 223:306-324. [PMID: 39134162 DOI: 10.1016/j.freeradbiomed.2024.07.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2024] [Revised: 07/01/2024] [Accepted: 07/30/2024] [Indexed: 08/17/2024]
Abstract
The systemic inflammatory response syndrome (SIRS) represents a self-amplifying cascade of inflammatory reactions and pathophysiological states triggered by infectious or non-infectious factors. The identification of disease targets and differential proteins in the liver (the unique and important immune organ) of SIRS mice treated with the lead compound D1 was conducted using the Genecards database and proteomic analysis, respectively. Subsequently, NOTCH1 was identified as the potential hub target via an intersection analysis between the aforementioned differentially expressed proteins and disease targets. Based on our previous research on the structure-activity relationship, we designed and synthesized a series of SIRS-related derivatives, wherein butyl, halogen, and ester groups were incorporated into benzophenone, aiming at exploring the anti-inflammatory protective action from the perspective of macrophage polarization. Notably, these derivatives exhibited a direct binding capability to the O-glucosylation site (SER496) or its vicinities (such as SER492, VAL485) of NOTCH1 using docking, SPR, DARTS, and CETSA techniques. Mechanistically, derivative D6 exerted anti-inflammatory effects via the dual NOTCH pathway. Firstly, it could inhibit NOTCH1 nuclear transcriptional activity, attenuate the interaction between NICD and RBPJK, concurrently suppress NF-κB and NLRP3 inflammasome (NLRP3, ASC, and cleaved CASP1) activation, and promote NICD (NOTCH1 active fragments) ubiquitination metabolism (the nuclear transcriptional pathway). Secondly, it might possess the ability to increase PGC1α level, subsequently, enhance ATP and MMP levels, mitigate ROS production, increase mitochondrial numbers, and ameliorate mitochondrial inflammatory damage (the mitochondrial pathway). Importantly, the activator Jagged1 could effectively reverse the aforementioned effects, while the inhibitor DAPT exhibited a synergistic effect, suggesting that the nuclear transcriptional regulation and mitochondrial regulation were both in a NOTCH1-dependent manner. Subsequently, it effectively alleviated the inflammatory response and preserved organ function as evidenced by up-regulating M2-type macrophage-related anti-inflammatory cytokines (IL10, TGFβ, CD206, and ARG1) and down-regulating M1-type macrophage-related pro-inflammatory cytokines (NO, IL6, IL18, iNOS, TNFα, CD86, and IL1β). In a word, derivative D6 modulated macrophage polarization and effectively mitigated SIRS by targeting inhibition of the dual NOTCH pathway.
Collapse
Affiliation(s)
- Jiayu Song
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan 030001, PR China
| | - Dan Peng
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan 030001, PR China
| | - Yu Peng
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan 030001, PR China
| | - Guang Zhao
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan 030001, PR China
| | - Yuan Ren
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan 030001, PR China
| | - Lina Guo
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan 030001, PR China
| | - Luyao Ren
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan 030001, PR China
| | - Xiaohui Zhang
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan 030001, PR China
| | - Xiaoxia Xie
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan 030001, PR China
| | - Yajie Zhang
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan 030001, PR China
| | - Lingya Cao
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan 030001, PR China
| | - Yunlan Li
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan 030001, PR China; School of Public Health, Shaanxi University of Chinese Medicine, Xi'an 712046, PR China.
| |
Collapse
|
2
|
Moussavi N, van der Ent W, Diallo D, Sanogo R, Malterud KE, Esguerra CV, Wangensteen H. Inhibition of Seizure-Like Paroxysms and Toxicity Effects of Securidaca longepedunculata Extracts and Constituents in Zebrafish Danio rerio. ACS Chem Neurosci 2024; 15:617-628. [PMID: 38270158 PMCID: PMC10853935 DOI: 10.1021/acschemneuro.3c00642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2023] [Revised: 01/08/2024] [Accepted: 01/15/2024] [Indexed: 01/26/2024] Open
Abstract
Plants used in traditional medicine in the management of epilepsy could potentially yield novel drug compounds with antiepileptic properties. The medicinal plant Securidaca longepedunculata is widely used in traditional medicine in the African continent, and epilepsy is among several indications. Limited knowledge is available on its toxicity and medicinal effects, such as anticonvulsant activities. This study explores the potential in vivo inhibition of seizure-like paroxysms and toxicity effects of dichloromethane (DCM) and ethanol (EtOH) extracts, as well as isolated xanthones and benzoates of S. longepedunculata. Ten phenolic compounds were isolated from the DCM extract. All of the substances were identified by nuclear magnetic resonance spectroscopy. Assays for toxicity and inhibition of pentylenetetrazole (PTZ)-induced seizure-like paroxysms were performed in zebrafish larvae. Among the compounds assessed in the assay for maximum tolerated concentration (MTC), benzyl-2-hydroxy-6-methoxy-benzoate (MTC 12.5 μM), 4,8-dihydroxy-1,2,3,5,6-pentamethoxyxanthone (MTC 25 μM), and 1,7-dihydroxy-4-methoxyxanthone (MTC 6.25 μM) were the most toxic. The DCM extract, 1,7-dihydroxy-4-methoxyxanthone and 2-hydroxy-1,7-dimethoxyxanthone displayed the most significant inhibition of paroxysms by altering the locomotor behavior in GABAA receptor antagonist, PTZ, which induced seizures in larval zebrafish. The EtOH extract, benzyl benzoate, and benzyl-2-hydroxy-6-methoxy-benzoate unexpectedly increased locomotor activity in treated larval zebrafish and decreased locomotor activity in nontreated larval zebrafish, seemingly due to paradoxical excitation. The results reveal promising medicinal activities of this plant, contributing to our understanding of its use as an antiepileptic drug. It also shows us the presence of potentially new lead compounds for future drug development.
Collapse
Affiliation(s)
- Nastaran Moussavi
- Section
for Pharmaceutical Chemistry, Department of Pharmacy, University of Oslo, P.O. Box 1068, Oslo 0316, Norway
| | - Wietske van der Ent
- NCMM,
Chemical Neuroscience Group, Centre for Molecular Medicine Norway,
Faculty of Medicine, University of Oslo, Oslo 0349, Norway
| | - Drissa Diallo
- Department
of Traditional Medicine, National Institute
of Public Health, PB, Bamako 1746, Mali
- Faculty
of Pharmacy, University of Sciences, Techniques
and Technologies of Bamako (USTTB), Bamako 1746, Mali
| | - Rokia Sanogo
- Department
of Traditional Medicine, National Institute
of Public Health, PB, Bamako 1746, Mali
- Faculty
of Pharmacy, University of Sciences, Techniques
and Technologies of Bamako (USTTB), Bamako 1746, Mali
| | - Karl E. Malterud
- Section
for Pharmaceutical Chemistry, Department of Pharmacy, University of Oslo, P.O. Box 1068, Oslo 0316, Norway
| | - Camila V. Esguerra
- Section
for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, P.O.
Box 1068, Oslo 0316, Norway
| | - Helle Wangensteen
- Section
for Pharmaceutical Chemistry, Department of Pharmacy, University of Oslo, P.O. Box 1068, Oslo 0316, Norway
| |
Collapse
|
3
|
Song J, Ren L, Ren Z, Ren X, Qi Y, Qin Y, Zhang X, Ren Y, Li Y. SIRT1-dependent mitochondrial biogenesis supports therapeutic effects of 4-butyl-polyhydroxybenzophenone compounds against NAFLD. Eur J Med Chem 2023; 260:115728. [PMID: 37625288 DOI: 10.1016/j.ejmech.2023.115728] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2023] [Revised: 08/12/2023] [Accepted: 08/13/2023] [Indexed: 08/27/2023]
Abstract
The mitochondria have been identified as key targets in nonalcoholic fatty liver disease (NAFLD), one of the most prevalent chronic liver damage diseases globally. Meanwhile, the biological information analysis in this study revealed that SIRT1, PPARG, PPARA, and PPARGC1A (mitochondrial biogenesis-related proteins) were NAFLD therapeutic targets. Therefore, the design and synthesis of targeted drugs that promote mitochondrial biogenesis and improve mitochondrial function are particularly important for NAFLD treatment. Recently, we introduced butyls, hydroxyls, and halogens to benzophenone and synthesized a series of NAFLD-related 4-butylpolyhydroxybenzophenone compounds, aiming at investigating the hepatoprotective activity from the aspect of mitochondrial biogenesis. The structure-activity relationship demonstrated that hydroxyl and ketone groups were active groups interacting with mitochondrial biogenesis proteins (SIRT1 and PGC1α), and the activity was stronger when the o-hydroxyl group was present on the benzene ring. In contrast, the activity was little affected by the presence of the p-hydroxyl group, m-hydroxyl group, butyl group type, or halogen. In addition, in vitro studies confirmed that these compounds could directly bind to SIRT1 and PGC1α, markedly promote their interaction, significantly increase the expression of proteins and genes related to mitochondrial biogenesis (SIRT1, PGC1α, NRF1, TFAM, COX1, and ND6) and subsequently ameliorate mitochondria dysfunction, which was evidenced by the decreased ROS, upregulated ATP production, increased MMP, and enhanced mitochondrial number. According to the outcomes of our in vitro and in vivo experiments, 4-butyl-polyhydroxybenzophenone compounds could also effectively reduce the formation of lipid droplets and liver injury index (ALT, AST, LDH, AKP, γ-GT, and GDH) and improve the level of antioxidant enzymes (GSH and SOD). Particularly, the treatment of these compounds after a high-fat diet could significantly reduce body weight, decrease liver coefficient, attenuate liver damage, and ameliorate lipid accumulation in rat liver, demonstrating their therapeutic effects on NAFLD. Mechanistically, 4-butyl-polyhydroxybenzophenone compounds promoted mitochondrial biogenesis and eventually prevented NAFLD liver injury by activating the PGC1α signaling pathway in a SIRT1-dependent manner, which was strongly supported by SIRT1 inhibitor EX527.
Collapse
Affiliation(s)
- Jiayu Song
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan, 030001, PR China
| | - Luyao Ren
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan, 030001, PR China
| | - Zhenzhu Ren
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan, 030001, PR China
| | - Xing Ren
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan, 030001, PR China
| | - Yang Qi
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan, 030001, PR China
| | - Yuxi Qin
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan, 030001, PR China
| | - Xiaohui Zhang
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan, 030001, PR China
| | - Yuan Ren
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan, 030001, PR China
| | - Yunlan Li
- School of Pharmaceutical Science, Shanxi Medical University, Taiyuan, 030001, PR China; School of Public Health, Shaanxi University of Chinese Medicine, Xi'an, 712046, PR China.
| |
Collapse
|
4
|
Ochora DO, Kakudidi EK, Namukobe J, Ipulet P, Wakoli DM, Okore W, Mwakio EW, Yeda RA, Cheruiyot AC, Juma DW, Andagalu B, Roth AL, Ogutu BR, Yenesew A, Akala HM. Synergism in Antiplasmodial Activities of Artemether and Lumefantrine in Combination with Securidaca longipedunculata Fresen (Polygalaceae). PLANTS (BASEL, SWITZERLAND) 2021; 11:47. [PMID: 35009051 PMCID: PMC8747340 DOI: 10.3390/plants11010047] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Revised: 11/29/2021] [Accepted: 12/01/2021] [Indexed: 11/16/2022]
Abstract
Malaria is the most lethal parasitic disease in the world. The frequent emergence of resistance by malaria parasites to any drug is the hallmark of sustained malaria burden. Since the deployment of artemisinin-based combination therapies (ACTs) it is clear that for a sustained fight against malaria, drug combination is one of the strategies toward malaria elimination. In Sub-Saharan Africa where malaria prevalence is the highest, the identification of plants with a novel mechanism of action that is devoid of cross-resistance is a feasible strategy in drug combination therapy. Thus, artemether and lumefantrine were separately combined and tested with extracts of Securidaca longipedunculata, a plant widely used to treat malaria, at fixed extract-drug ratios of 4:1, 3:1, 1:1, 1:2, 1:3, and 1:4. These combinations were tested for antiplasmodial activity against three strains of Plasmodium falciparum (W2, D6, and DD2), and seven field isolates that were characterized for molecular and ex vivo drug resistance profiles. The mean sum of fifty-percent fractional inhibition concentration (FIC50) of each combination and singly was determined. Synergism was observed across all fixed doses when roots extracts were combined with artemether against D6 strain (FIC50 0.403 ± 0.068) and stems extract combined with lumefantrine against DD2 strain (FIC50 0.376 ± 0.096) as well as field isolates (FIC50 0.656 ± 0.067). Similarly, synergism was observed in all ratios when leaves extract were combined with lumefantrine against W2 strain (FIC50 0.456 ± 0.165). Synergism was observed in most combinations indicating the potential use of S. longipedunculata in combination with artemether and lumefantrine in combating resistance.
Collapse
Affiliation(s)
- Douglas O. Ochora
- Department of Plant Sciences, Microbiology & Biotechnology, College of Natural Sciences, Makerere University, Kampala P.O. Box 7062-10207, Uganda; (E.K.K.); (P.I.)
| | - Esezah K. Kakudidi
- Department of Plant Sciences, Microbiology & Biotechnology, College of Natural Sciences, Makerere University, Kampala P.O. Box 7062-10207, Uganda; (E.K.K.); (P.I.)
| | - Jane Namukobe
- Department of Chemistry, College of Natural Sciences, Makerere University, Kampala P.O. Box 7062-10207, Uganda;
| | - Perpetua Ipulet
- Department of Plant Sciences, Microbiology & Biotechnology, College of Natural Sciences, Makerere University, Kampala P.O. Box 7062-10207, Uganda; (E.K.K.); (P.I.)
| | - Dancan M. Wakoli
- Department of Biochemistry and Molecular Biology, Egerton University, Njoro P.O. Box 536-20115, Kenya;
- United States Army Medical Research Directorate-Kenya (USAMRD-K), Kenya Medical Research Institute (KEMRI)—Walter Reed Project, Kisumu, Kisumu P.O. Box 54-40100, Kenya;
| | - Winnie Okore
- United States Army Medical Research Directorate-Kenya (USAMRD-K), Kenya Medical Research Institute (KEMRI)—Walter Reed Project, Kisumu, Kisumu P.O. Box 54-40100, Kenya;
- Department of Biomedical Sciences and Technology, School of Public Health and Community Development, Maseno University, Maseno P.O. Box Private Bag-40105, Kenya; (E.W.M.); (R.A.Y.); (A.C.C.); (D.W.J.); (B.A.); (A.L.R.)
| | - Edwin W. Mwakio
- Department of Biomedical Sciences and Technology, School of Public Health and Community Development, Maseno University, Maseno P.O. Box Private Bag-40105, Kenya; (E.W.M.); (R.A.Y.); (A.C.C.); (D.W.J.); (B.A.); (A.L.R.)
| | - Redempthah A. Yeda
- Department of Biomedical Sciences and Technology, School of Public Health and Community Development, Maseno University, Maseno P.O. Box Private Bag-40105, Kenya; (E.W.M.); (R.A.Y.); (A.C.C.); (D.W.J.); (B.A.); (A.L.R.)
| | - Agnes C. Cheruiyot
- Department of Biomedical Sciences and Technology, School of Public Health and Community Development, Maseno University, Maseno P.O. Box Private Bag-40105, Kenya; (E.W.M.); (R.A.Y.); (A.C.C.); (D.W.J.); (B.A.); (A.L.R.)
| | - Dennis W. Juma
- Department of Biomedical Sciences and Technology, School of Public Health and Community Development, Maseno University, Maseno P.O. Box Private Bag-40105, Kenya; (E.W.M.); (R.A.Y.); (A.C.C.); (D.W.J.); (B.A.); (A.L.R.)
| | - Ben Andagalu
- Department of Biomedical Sciences and Technology, School of Public Health and Community Development, Maseno University, Maseno P.O. Box Private Bag-40105, Kenya; (E.W.M.); (R.A.Y.); (A.C.C.); (D.W.J.); (B.A.); (A.L.R.)
| | - Amanda L. Roth
- Department of Biomedical Sciences and Technology, School of Public Health and Community Development, Maseno University, Maseno P.O. Box Private Bag-40105, Kenya; (E.W.M.); (R.A.Y.); (A.C.C.); (D.W.J.); (B.A.); (A.L.R.)
| | - Bernhards R. Ogutu
- Centre for Clinical Research, Kenya Medical Research Institute (KEMRI), Kisumu P.O. Box 1578-40100, Kenya;
| | - Abiy Yenesew
- Department of Chemistry, University of Nairobi, Nairobi P.O. Box 30197-00100, Kenya;
| | - Hoseah M. Akala
- Department of Biomedical Sciences and Technology, School of Public Health and Community Development, Maseno University, Maseno P.O. Box Private Bag-40105, Kenya; (E.W.M.); (R.A.Y.); (A.C.C.); (D.W.J.); (B.A.); (A.L.R.)
| |
Collapse
|